Clinical Trial Update: CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating CD19/BCMA CAR-T cell therapy for refractory or moderate-to-severe systemic lupus erythematosus. The study is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• CD19/BCMA CAR-T Cell Therapy

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: RECRUITING